BioCentury | Jun 25, 2009
Distillery Therapeutics

Indication: Infectious disease

...EV71 interaction in viral pathogenesis and the development of a mouse model expressing human SCARB2. Y's Therapeutics Co. Ltd.'s...
BioCentury | Jan 8, 2009
Cover Story

Taking the inflammation out of epilepsy

...plaque psoriasis. Another is YSPSL , a fusion protein of PSGL-1 and human IgG1 from Y's Therapeutics Co. Ltd....
...risk of seizure, he added, "with rigorous monitoring for adverse events like opportunistic infection." At Y's Therapeutics...
...Amsterdam, the Netherlands University of Verona , Verona, Italy Urigen Pharmaceuticals Inc. (OtcBB:URGP), Burlingame, Calif. Y's Therapeutics Co. Ltd....
BioCentury | Dec 11, 2008
Distillery Therapeutics

This week in therapeutics

...PSGL-1-targeted therapeutics to treat epilepsy. YSPSL, a recombinant fusion of PSGL-1 and human IgG1 from Y's Therapeutics Co. Ltd....
BioCentury | Jan 7, 2008
Company News

Trellis Bioscience management update

...John Wulf as EVP of business operations and CBO, formerly president, COO and CBO of Y's Therapeutics Co. Ltd. WIR...
BioCentury | Apr 30, 2007
Clinical News

YSPSL: Completed Phase II enrollment

...the trial will be presented in May at the American Transplant Congress in San Francisco. Y's Therapeutics Co. Ltd....
BioCentury | Apr 23, 2007
Clinical News

Autologous nonmyeloablative hematopoietic stem cell transplantation: Phase I/II data

Researchers from the University of Sao Paulo , Y's Therapeutic (Tokyo, Japan) and Northwestern University published in the Journal of the American Medical Association results of a Brazilian Phase I/II study in which beta cell function...
BioCentury | Apr 18, 2007
Clinical News

Stem cell transplants prolong insulin independence

...Researchers from the University of Sao Paulo, Y's Therapeutics (Tokyo, Japan) and Northwestern University published in the...
BioCentury | Sep 25, 2006
Company News

Chromos, Y's Therapeutics deal

...the product. Financial terms were not disclosed. Chromos Molecular Systems Inc . (TSX:CHR), Burnaby, B.C. Y's Therapeutics...
BioCentury | Jul 24, 2006
Clinical News

YSPSL regulatory update

...recombinant molecule resulting from the fusion of P selectin glycoprotein ligand-1 (PSGL-1) and human IgG1. Y's Therapeutics...
BioCentury | Dec 5, 2005
Clinical News

YSPSL: Phase II started

...Incidence of delayed graft function (DGF) Status: Phase II started Milestone: Complete Phase II (2007) Y's Therapeutics...
...the trial will be open-label and dose-escalating, and the second will be double-blinded and placebo-controlled. Y's Therapeutics Co. Ltd....
Items per page:
1 - 10 of 21
BioCentury | Jun 25, 2009
Distillery Therapeutics

Indication: Infectious disease

...EV71 interaction in viral pathogenesis and the development of a mouse model expressing human SCARB2. Y's Therapeutics Co. Ltd.'s...
BioCentury | Jan 8, 2009
Cover Story

Taking the inflammation out of epilepsy

...plaque psoriasis. Another is YSPSL , a fusion protein of PSGL-1 and human IgG1 from Y's Therapeutics Co. Ltd....
...risk of seizure, he added, "with rigorous monitoring for adverse events like opportunistic infection." At Y's Therapeutics...
...Amsterdam, the Netherlands University of Verona , Verona, Italy Urigen Pharmaceuticals Inc. (OtcBB:URGP), Burlingame, Calif. Y's Therapeutics Co. Ltd....
BioCentury | Dec 11, 2008
Distillery Therapeutics

This week in therapeutics

...PSGL-1-targeted therapeutics to treat epilepsy. YSPSL, a recombinant fusion of PSGL-1 and human IgG1 from Y's Therapeutics Co. Ltd....
BioCentury | Jan 7, 2008
Company News

Trellis Bioscience management update

...John Wulf as EVP of business operations and CBO, formerly president, COO and CBO of Y's Therapeutics Co. Ltd. WIR...
BioCentury | Apr 30, 2007
Clinical News

YSPSL: Completed Phase II enrollment

...the trial will be presented in May at the American Transplant Congress in San Francisco. Y's Therapeutics Co. Ltd....
BioCentury | Apr 23, 2007
Clinical News

Autologous nonmyeloablative hematopoietic stem cell transplantation: Phase I/II data

Researchers from the University of Sao Paulo , Y's Therapeutic (Tokyo, Japan) and Northwestern University published in the Journal of the American Medical Association results of a Brazilian Phase I/II study in which beta cell function...
BioCentury | Apr 18, 2007
Clinical News

Stem cell transplants prolong insulin independence

...Researchers from the University of Sao Paulo, Y's Therapeutics (Tokyo, Japan) and Northwestern University published in the...
BioCentury | Sep 25, 2006
Company News

Chromos, Y's Therapeutics deal

...the product. Financial terms were not disclosed. Chromos Molecular Systems Inc . (TSX:CHR), Burnaby, B.C. Y's Therapeutics...
BioCentury | Jul 24, 2006
Clinical News

YSPSL regulatory update

...recombinant molecule resulting from the fusion of P selectin glycoprotein ligand-1 (PSGL-1) and human IgG1. Y's Therapeutics...
BioCentury | Dec 5, 2005
Clinical News

YSPSL: Phase II started

...Incidence of delayed graft function (DGF) Status: Phase II started Milestone: Complete Phase II (2007) Y's Therapeutics...
...the trial will be open-label and dose-escalating, and the second will be double-blinded and placebo-controlled. Y's Therapeutics Co. Ltd....
Items per page:
1 - 10 of 21